FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304299> ?p ?o ?g. }

• W4367304299 abstract "<h3>Objective:</h3> NA <h3>Background:</h3> Iatrogenic neuroinflammation has been frequently reported in recent years owing to expanding biologic therapies for the treatment of a wide range of disorders including Psoriasis. Here we report a case of Central Nervous System (CNS) vasculitis after initiation of Risankizumab, a monoclonal antibody against Interleukin-23 (IL23) used to treat Psoriasis. <h3>Design/Methods:</h3> Case report. <h3>Results:</h3> A 29-year-old female with moderate psoriasis who was started on Risankizumab about one month prior, presented with encephalopathy and left temporal lobe focal seizures with refractory status epilepticus. Her MRI showed punctate infarcts and areas of enhancement in the left temporal lobe and leptomeninges overlying the left convexity. Extensive work up revealed increased Erythrocyte Sedimentation Rate (72 mm/hr) and positive Cardiolipin (IgM and IgG) and Beta-2 Glycoprotein (IgM and IgG) antibodies suggesting antiphospholipid syndrome (APS) for which she was started on anticoagulation. Lumbar puncture revealed normal opening pressure, glucose, protein and five nucleated cells. Oligoclonal bands, meningitis/encephalitis and autoimmune encephalitis panels were negative. Subsequent brain MRI showed new areas of ischemic lesions. Cerebral angiogram was unremarkable. Biopsy revealed focal perivascular lymphocytes (CD45 and CD3 immunohistochemical stained) infiltration in dural vessels consistent with small-vessel vasculitis. She was treated with high dose steroids with clinical improvement and subsequently planned to treat with Cyclophosphamide. Risankizumab was discontinued due to possible association. <h3>Conclusions:</h3> Iatrogenic neuroinflammation has been increasingly recognized during the new era of biological molecules and monoclonal antibodies for systemic inflammatory disorders and malignancies. Tumor necrosis factor inhibitors and immune checkpoint inhibitors are more commonly associated with neuroinflammation. To the best of our knowledge, this is the first reported case of APS and CNS vasculitis possibly associated with the initiation of IL23 inhibitor Risankizumab. Although causality cannot be established with a single case, it suggests a possible association. <b>Disclosure:</b> Dr. Cabrera Pulla has nothing to disclose. Dr. Amirjanyan has nothing to disclose. Qian Wu has nothing to disclose. Dr. Mui has nothing to disclose. Dr. Imitola has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis . The institution of Dr. Imitola has received research support from biogen. Dr. Imitola has a non-compensated relationship as a Board Member with National MS Society that is relevant to AAN interests or activities. Dr. Imitola has a non-compensated relationship as a Committee Member with International Society for Stem Cell Research that is relevant to AAN interests or activities. Dr. Coban has nothing to disclose." @default.
• W4367304299 created "2023-04-29" @default.
• W4367304299 creator A5009194583 @default.
• W4367304299 creator A5011738542 @default.
• W4367304299 creator A5015589637 @default.
• W4367304299 creator A5055994270 @default.
• W4367304299 creator A5066093926 @default.
• W4367304299 creator A5073620668 @default.
• W4367304299 date "2023-04-25" @default.
• W4367304299 modified "2023-10-14" @default.
• W4367304299 title "Cerebral Vasculitis in a patient receiving Risankizumab, an Inhibitor of Interleukin-23: First Case Report (P12-3.013)" @default.
• W4367304299 doi "https://doi.org/10.1212/wnl.0000000000202476" @default.
• W4367304299 hasPublicationYear "2023" @default.
• W4367304299 type Work @default.
• W4367304299 citedByCount "1" @default.
• W4367304299 countsByYear W43673042992023 @default.
• W4367304299 crossrefType "proceedings-article" @default.
• W4367304299 hasAuthorship W4367304299A5009194583 @default.
• W4367304299 hasAuthorship W4367304299A5011738542 @default.
• W4367304299 hasAuthorship W4367304299A5015589637 @default.
• W4367304299 hasAuthorship W4367304299A5055994270 @default.
• W4367304299 hasAuthorship W4367304299A5066093926 @default.
• W4367304299 hasAuthorship W4367304299A5073620668 @default.
• W4367304299 hasConcept C126322002 @default.
• W4367304299 hasConcept C142724271 @default.
• W4367304299 hasConcept C203014093 @default.
• W4367304299 hasConcept C2775934546 @default.
• W4367304299 hasConcept C2776015282 @default.
• W4367304299 hasConcept C2776429142 @default.
• W4367304299 hasConcept C2778621155 @default.
• W4367304299 hasConcept C2778754783 @default.
• W4367304299 hasConcept C2779134260 @default.
• W4367304299 hasConcept C71924100 @default.
• W4367304299 hasConceptScore W4367304299C126322002 @default.
• W4367304299 hasConceptScore W4367304299C142724271 @default.
• W4367304299 hasConceptScore W4367304299C203014093 @default.
• W4367304299 hasConceptScore W4367304299C2775934546 @default.
• W4367304299 hasConceptScore W4367304299C2776015282 @default.
• W4367304299 hasConceptScore W4367304299C2776429142 @default.
• W4367304299 hasConceptScore W4367304299C2778621155 @default.
• W4367304299 hasConceptScore W4367304299C2778754783 @default.
• W4367304299 hasConceptScore W4367304299C2779134260 @default.
• W4367304299 hasConceptScore W4367304299C71924100 @default.
• W4367304299 hasLocation W43673042991 @default.
• W4367304299 hasOpenAccess W4367304299 @default.
• W4367304299 hasPrimaryLocation W43673042991 @default.
• W4367304299 hasRelatedWork W1655558780 @default.
• W4367304299 hasRelatedWork W1968652867 @default.
• W4367304299 hasRelatedWork W1995792188 @default.
• W4367304299 hasRelatedWork W2035122201 @default.
• W4367304299 hasRelatedWork W2048499462 @default.
• W4367304299 hasRelatedWork W2106405153 @default.
• W4367304299 hasRelatedWork W2164284301 @default.
• W4367304299 hasRelatedWork W2165638835 @default.
• W4367304299 hasRelatedWork W2414677644 @default.
• W4367304299 hasRelatedWork W4237127843 @default.
• W4367304299 isParatext "false" @default.
• W4367304299 isRetracted "false" @default.
• W4367304299 workType "article" @default.